- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03955471
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)
August 16, 2022 updated by: Tesaro, Inc.
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- GSK Investigational Site
-
-
California
-
Duarte, California, United States, 91010
- GSK Investigational Site
-
Newport Beach, California, United States, 92663
- GSK Investigational Site
-
Orange, California, United States, 92868
- GSK Investigational Site
-
Solvang, California, United States, 93463
- GSK Investigational Site
-
-
Florida
-
Deerfield Beach, Florida, United States, 33442
- GSK Investigational Site
-
Miami, Florida, United States, 33136
- GSK Investigational Site
-
Orlando, Florida, United States, 32804
- GSK Investigational Site
-
Tampa, Florida, United States, 33612
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242-1009
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- GSK Investigational Site
-
Boston, Massachusetts, United States, 02215
- GSK Investigational Site
-
Burlington, Massachusetts, United States, 01805
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- GSK Investigational Site
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- GSK Investigational Site
-
-
New York
-
New York, New York, United States, 10022
- GSK Investigational Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- GSK Investigational Site
-
Cleveland, Ohio, United States, 44124
- GSK Investigational Site
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- GSK Investigational Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- GSK Investigational Site
-
Germantown, Tennessee, United States, 38138
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78731
- GSK Investigational Site
-
Fort Worth, Texas, United States, 76104
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion criteria:
- Participant must be female >=18 years of age, able to understand the study procedures, and subsequently agreed to participate in the study by providing written informed consent.
- Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer.
- Participants must be considered resistant to the last administered platinum therapy.
- Participants must have completed at least 1 but no more than 3 prior lines of therapy for advanced or metastatic ovarian cancer.
- Participants must have been previously treated with platinum-based regimen, taxane agent(s), and bevacizumab.
- Participant has measurable disease according to RECIST v.1.1.
- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participant has adequate organ function.
- Females with childbearing potential have a serum pregnancy test that is negative 72 prior first dose and are not breastfeeding. Participant must also agree to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment.
- Participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable BRCA testing and PD-L1 testing. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor.
- Participant must agree to complete health-related quality of life (HRQoL) questionnaires throughout the study.
Exclusion Criteria:
- Participant who experienced disease progression within 3 months (12 weeks or 84 days) of first-line platinum therapy.
- Participants with a known deleterious or suspected BRCA 1 or 2 mutation.
- Participant has received prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent.
- Participant has received prior therapy with a PARP-1/PARP-2 inhibitor.
- Participant has a known hypersensitivity to dostarlimab (TSR-042), Niraparib, their components, or their excipients.
- Participant has a known history of myelodysplastic syndrome or acute myeloid leukemia.
- Participant has not recovered from prior chemotherapy induced adverse events.
- Participant has a known diagnosis of immunodeficiency or is receiving systemic steroid therapy exceeding an equivalent of prednisone 10 mg daily or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
- Participant is currently participating in a treatment study or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment.
- Participant has received prior systemic anticancer therapy including cytotoxic chemotherapy, hormonal therapy given with the intention to treat ovarian cancer, or biological therapy within 3 weeks of the first dose of study treatment.
- Participant has received live vaccine within 14 days of planned start of study therapy
- Participant has symptomatic uncontrolled brain or leptomeningeal metastases. (If investigator feels participant symptoms are not symptomatic, participants can undergo a scan to confirm for eligibility).
- Participant had major surgery with 4 weeks of starting the first dose of the study treatment or participant has not recovered from any effects of any major surgery.
- Participant has a known additional malignancy that progressed or required active treatment within the last 2 years.
- Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active controlled infection.
- Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study.
- Participant has known active hepatitis B (hepatitis B surface antigen reactive) or hepatitis C (hepatitis C virus ribonucleic acid, qualitative).
Participant with a known history of human immunodeficiency virus (HIV) are allowed if they meet all of the following criteria:
- Cluster of differentiation 4 >=350/microliter (μL) and viral load <400 copies/milliliter (mL)
- No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months prior to enrollment
- No history of HIV-associated malignancy for the past 5 years
- Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV started >4 weeks prior to study enrollment
- Participant is immunocompromised. Participants with splenectomy are allowed.
- Participant has an ongoing bowel obstruction or has other conditions that would lead to impaired absorption of oral niraparib.
- Participant has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Niraparib+Dostarlimab (TSR-042)
Participants with body weight ≥77 kilogram (kg) and platelet count ≥150,000/microliter (μL) at baseline were administered Niraparib 300 milligram (mg) once daily (QD) and participants with body weight <77 kg or platelet count <150,000/μL at baseline were administered Niraparib 200 mg QD.
Niraparib was administered continuously until Progressive disease (PD) or toxicity.
Dostarlimab (TSR-042) was administered as an intravenous (IV) infusion of 500 mg once every three weeks (Q3W) from Cycle 1 Day 1 through Cycle 4. Beginning at Cycle 5, Dostarlimab (TSR-042) was administered via an IV infusion of 1000 mg on Day 1 of each 6-week cycle until PD or toxicity, up to 27 months.
|
Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
Other Names:
TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)
Time Frame: Up to approximately 22 months
|
ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or partial response (PR), as determined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria based on Investigator assessment and computed tomography (CT) scans were commonly used for tumor imaging.
|
Up to approximately 22 months
|
ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status
Time Frame: Up to approximately 22 months
|
ORR is defined as the percentage of participants who have achieved confirmed CR or PR, as determined by RECIST v1.1 criteria based on Investigator assessment and CT scans were commonly used for tumor imaging.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with combined positive score (vCPS) >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR) in Participants With PROC
Time Frame: Up to approximately 22 months
|
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
|
Up to approximately 22 months
|
DOR in Participants With PROC Who Have PD-L 1 Positive Status
Time Frame: Up to approximately 22 months
|
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with vCPS >=5% was used as specified cut-point for the assessment of PD-L1 patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
Progression-free Survival (PFS) in Participants With PROC
Time Frame: Up to approximately 22 months
|
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
|
Up to approximately 22 months
|
PFS in Participants With PROC Who Have PD-L 1 Positive Status
Time Frame: Up to approximately 22 months
|
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with a vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
Overall Survival (OS) in Participants With PROC
Time Frame: Up to approximately 22 months
|
OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause.
|
Up to approximately 22 months
|
OS in Participants With PROC Who Have PD-L 1 Positive Status
Time Frame: Up to approximately 22 months
|
OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
Disease Control Rate (DCR) in Participants With PROC
Time Frame: Up to approximately 22 months
|
DCR is defined as the percentage of participants who have achieved best overall response (BOR) of CR, PR, or stable disease (SD) per RECIST v.1.1 based on the investigator's assessment.
|
Up to approximately 22 months
|
DCR in Participants With PROC Who Have PD-L 1 Positive Status
Time Frame: Up to approximately 22 months
|
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on the investigator's assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
ORR in Participants With PROC Based on Independent Review Committee (IRC) Assessment
Time Frame: Up to approximately 22 months
|
ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment.
|
Up to approximately 22 months
|
ORR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with a vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
DOR in Participants With PROC Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment.
|
Up to approximately 22 months
|
DOR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with a vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
PFS in Participants With PROC Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee Assessment.
|
Up to approximately 22 months
|
PFS in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on IRC Assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with a vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
DCR in Participants With PROC Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on IRC Assessment.
|
Up to approximately 22 months
|
DCR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment
Time Frame: Up to approximately 22 months
|
DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on Independent Review Committee Assessment.
PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive.
Any PD-L1 positive tissue sample with vCPS >=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC.
vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.
|
Up to approximately 22 months
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs) and Adverse Event of Special Interest (AESI)
Time Frame: Up to approximately 27 months
|
An AE is any untoward medical occurrence in a patient administered with a medicinal product and that does which may or may not have a causal relationship with this treatment.
A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
TEAEs are any event that occurred between first dose of study drug up to 22 months, which were absent before treatment or that had worsened relative to pretreatment state.
AESI were any AE (serious or non-serious) that is of scientific and medical concern specific to the study treatment, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was done.
|
Up to approximately 27 months
|
Number of Participants With Grade Shift From Baseline in Hematology
Time Frame: Up to approximately 27 months
|
Blood samples were collected for the analysis of hematology parameters and each parameter was graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.3.
Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
Data has been presented for the number of participants with hematology grade shifts from baseline grade to grade 3 and 4 for each parameter.
|
Up to approximately 27 months
|
Number of Participants With Grade Shift From Baseline in Plasma Chemistry
Time Frame: Up to approximately 27 months
|
Blood samples were collected and the clinical chemistry parameters assessed were Albumin (Alb), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, total bilirubin (TB), creatinine, glucose, magnesium and potassium.
The Grade shift post baseline data of each parameter from Grade 0 through Grade 4 was based on the CTCAE version 4.03, grading scale, as per intensity, namely Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
Data has been presented for the number of participants with plasma chemistry grade shifts from baseline grade to grade 3 and 4 for each parameter.
|
Up to approximately 27 months
|
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Time Frame: Up to approximately 27 months
|
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values.
The minimum (min) and maximum (max) change from baseline values have been reported.
|
Up to approximately 27 months
|
Change From Baseline in Pulse Rate
Time Frame: Up to approximately 27 months
|
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values.
The minimum (min) and maximum (max) change from baseline values have been reported.
|
Up to approximately 27 months
|
Change From Baseline in Temperature
Time Frame: Up to approximately 27 months
|
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values.
The minimum (min) and maximum (max) change from baseline values have been reported.
|
Up to approximately 27 months
|
Change From Baseline in Prothrombin International Normalized Ratio
Time Frame: Baseline and up to approximately 27 months
|
Blood samples were collected to evaluate Prothrombin International Normalized Ratio (INR).
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
|
Baseline and up to approximately 27 months
|
Change in Baseline in Activated Partial Thromboplastin Time
Time Frame: Baseline and up to approximately 27 months
|
Blood samples were planned to be collected to evaluate activated partial thromboplastin time (APTT).
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
|
Baseline and up to approximately 27 months
|
Change From Baseline in Thyrotropin
Time Frame: Baseline and up to approximately 27 months
|
Blood samples were collected to evaluate thyrotropin at indicated time points.
Baseline was defined as the most recent measurement prior to the first administration of study treatment.
Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
|
Baseline and up to approximately 27 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 3, 2019
Primary Completion (Actual)
August 18, 2021
Study Completion (Actual)
January 12, 2022
Study Registration Dates
First Submitted
May 16, 2019
First Submitted That Met QC Criteria
May 17, 2019
First Posted (Actual)
May 20, 2019
Study Record Updates
Last Update Posted (Actual)
September 10, 2022
Last Update Submitted That Met QC Criteria
August 16, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Niraparib
Other Study ID Numbers
- 213353
- 3000-02-006 (Other Identifier: Tesaro)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Neoplasms
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Ovarian Carcinoma | Ovarian Neoplasm | Ovarian Clear Cell Tumor | Adnexal Mass | Ovarian Endometrioid Tumor | Ovarian Serous Tumor | Borderline Ovarian Epithelial TumorUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
-
Maastricht University Medical CenterVieCuri Medical Centre; Orbis Medical Centre; St.Jans Gasthuis Weert; Laurentius...TerminatedOvarian Cancer | Ovarian Carcinoma | Ovarian Cyst | Ovarian MassNetherlands
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Health Science Center of Xi'an Jiaotong UniversityRecruitingOvarian Cancer | Cancer of the Ovary | Ovarian Neoplasm | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Ovary Neoplasm | Cancer of Ovary | Cancer, Ovarian | Ovarian Cancers | Neoplasm, Ovarian | Neoplasm, Ovary | Neoplasms, Ovary | Cancer, Ovarian Stromal | Cancers, Ovary | Ovary Cancers | Cancers, OvarianChina
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Medical University of LublinCompletedOvarian Cancer | Unexplained Infertility | Borderline Ovarian Tumors | Benign Ovarian TumorPoland
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
Clinical Trials on Niraparib
-
Tesaro, Inc.Completed
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Tesaro, Inc.Active, not recruiting
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Chongqing University Cancer HospitalRecruiting
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate AdenocarcinomaUnited States
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Hunan Cancer HospitalUnknown
-
Lei LiRecruitingChemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian CancerChina